🎙️🩺Dr.Chih-ho Hong shares the intriguing shifts in the treatment landscape for #atopic #dermatitis and how #patient #access is shaping choice.

🌍The World Congress of #Dermatology isn’t just any conference – it really is the Olympics of #Dermatology, and Dr. Hong gives us a peek behind the curtains, tracing his journey from a fresh resident to a podium regular.

Tune in to learn, laugh, and leap into the world of global #AD trends, and hear Dr.Hong's #Singapore #Story 🌍🩺🥇

🎤 Only on the Skin and Joints Podcast
 

EPISODE Supported by an IME Grant from Pfizer
 

ABOUT DR.CHIH-HO HONG

🎧  Dr. Hong is a board certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office based dermatology clinic with a focus on clinical research. He is a Clinical Assistant Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.

Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.

📻www.skinandjoints.ca

✉️[email protected]

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨 PART 2! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.
 

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH -of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC. And awarded Master CRA in

Episode Learning Objectives

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

By the end of this episode, listeners should be able to:

• Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.
• Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.
• Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.
• Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.
• Discuss the future of TNFA-i and RWE in clinical practice.
• Identify factors to consider when differentiating between biosimilars during a switch.
• Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.
• Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

📻www.skinandjoints.ca

✉️[email protected]

🎙️🌟 𝘽𝙞𝙤𝙨𝙞𝙢𝙞-𝙇𝙖𝙪𝙣𝙘𝙝: 𝘼 𝙏𝙖𝙡𝙚 𝙤𝙛 𝙎𝙠𝙞𝙣, 𝙅𝙤𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘽𝙤𝙡𝙙 𝘽𝙚𝙜𝙞𝙣𝙣𝙞𝙣𝙜𝙨! 🌟🎙️

🚀#𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗵𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 & 𝘄𝗲'𝘃𝗲 𝗴𝗼𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘀𝗰𝗼𝗼𝗽!

𝗢𝗻𝘁𝗮𝗿𝗶𝗼 𝗯𝗮𝘀𝗲𝗱 #rheumatologist, 𝗗𝗿.Carter Thorne 𝗹𝗼𝗼𝗸s 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝗮𝘀𝗰𝗶𝗻𝗮𝘁𝗶𝗻𝗴 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 (RWE) 𝗳𝗼𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀💉🔍𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗥𝗪𝗘 transition 𝗱𝗮𝘁𝗮 𝘁𝗿𝗲𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗶𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗼𝗻 𝗷𝗼𝗶𝗻𝘁 & 𝘀𝗸𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀! 💪🤓
𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗵𝗼𝘄 𝘁𝗼 𝗯𝗲 𝗮 #𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 wizard 💼🏆 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗲𝗿𝗿𝗮𝗶𝗻 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗱𝗮𝘆-𝘁𝗼-𝗱𝗮𝘆 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 🗺️👩‍⚕️👨‍⚕️

👨‍⚕️Dr.Thorne 𝙞𝙨 𝙞𝙣𝙫𝙤𝙡𝙫𝙚𝙙 𝙞𝙣 𝘾𝘼𝙏𝘾𝙃 (𝘾𝙖𝙣𝙖𝙙𝙞𝙖𝙣 𝙀𝙖𝙧𝙡𝙮 𝘼𝙧𝙩𝙝𝙧𝙞𝙩𝙞𝙨 𝘾𝙤𝙝𝙤𝙧𝙩), 𝙊𝘽𝙍𝙄 (𝙊𝙣𝙩𝙖𝙧𝙞𝙤 𝘽𝙚𝙨𝙩 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚𝙨 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙄𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚) 𝙖𝙣𝙙 𝙖𝙩 𝙡𝙤𝙘𝙖𝙡, 𝙥𝙧𝙤𝙫𝙞𝙣𝙘𝙞𝙖𝙡 𝙖𝙣𝙙 𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙢𝙤𝙙𝙚𝙡𝙨 𝙤𝙛 𝙘𝙖𝙧𝙚 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨.
 

🎧 🎉Dr. Thorne is an Assistant Professor at the University of Toronto, and is on the Consultant Staff at Southlake Regional Health Centre in Newmarket, Ontario where he was Chief of the Division of Rheumatology and Director of The Arthritis Program; the latter is a unique Inter-Professional care program established to optimize outcomes for people who have arthritis and other rheumatic disorders. He is sought for his expertise in developing Outcome Based clinical Programs, not only in Arthritis Care, but also Shared Care in a Comprehensive Musculoskeletal Program, Wound Management and NeuroRehab/Stroke Care.

He is active in Clinical Research as Principal Investigator with The Arthritis Program Research Group Inc. As part of a strategic interest in identifying ‘Best Practices’, he has established an Early Arthritis Clinic, collaborating with a national initiative, CATCH of which he is a member of the Scientific Advisory Committee and Operations Director, and an Osteoporosis Intervention Clinic. He sits on the Steering and Scientific Committee of the Ontario Best Practices Research Initiative, a collaborative attempt among stakeholders to describe and disseminate outcomes and best practices, in the management of Rheumatoid Arthritis. He was an active Investigator and participant in the successful Canadian Rheumatology Research Consortium and served as Secretary-Treasurer, until its conclusion in 2014. He is a founding member of the Ontario Rheumatology Association and Past-President (2006-10). He is past President of the Canadian Rheumatology Association (2012-2014) and past Secretary-Treasurer (1996-2004). He is past Secretary-Treasurer of PANLAR, and has served on the Steering Committee of CARE, a European-based group interested in the non-pharmacologic management of arthritis. He was a member of the Rehab Committee of the American College of Rheumatology 2003-09 and served as Chair pf the Committee, till its dissolution.

He has been involved in improving care for those with arthritis through the above initiatives, and his work with CRA and ORA, in Best Practices identification and dissemination strategies, and development of Models of Care frameworks (ORA); and improving the health of the community, as a past member of the York Region District Health Council (DHC) and past-Chair of the amalgamated Simcoe-York DHC. Since the recent cancellation of TAP by Southlake, he has become energized in the establishment of a Not-for-Profit organization (Centre of Arthritis Excellence - CArE) to develop a community-based MSK program, the first of its kind supported by the Ontario Ministry of Health, as a Portal of MSK Care, utilizing an Inter-Professional MoC, opening September 2022.

Dr. Thorne has been recognized by his colleagues and peers, with the ORA Distinguished Rheumatologist Award (2010), the CRA Distinguished Rheumatologist Award (2015), and the Queen Elizabeth II Diamond Jubilee Medal (2012), and has been recognized as a Master of the American College of Rheumatology (2016), in Washington DC. 

Episode Learning Objectives

In this podcast episode, we will explore the value of Real-World Evidence (RWE) in biosimilars for daily clinical practice decisions. Our discussion will be divided into two parts: the first part will focus on RWE, and the second part will center on the biosimilar switch experience.

By the end of this episode, listeners should be able to:

• Understand the concept of Real-World Evidence (RWE) in the biosimilar space and its significance for healthcare professionals.
• Recognize the benefits and advantages of RWE, such as switch data and varying patient demographics.
• Analyze the impact of RWE on therapeutic decision-making for inflammatory joint management.
• Differentiate between various types of RWE in the biosimilar space (e.g., registry CATCH cohort, data based on patient records, health economic research) and evaluate their credibility and methodology.
• Discuss the future of TNFA-i and RWE in clinical practice.
• Identify factors to consider when differentiating between biosimilars during a switch.
• Address potential pain points during the biosimilar switch process, such as managing patient expectations, mitigating the nocebo effect, and navigating access.
• Share insights and strategies for healthcare professionals to approach the biosimilar switch process effectively in their clinic and practice workflow

📻www.skinandjoints.ca

✉️[email protected]

🎧 🎉🎙️ Breaking Ground: A Co-Managed Approach to Psoriatic Arthritis - Real World Insights from Dr. Jan Dutz and Dr. Jonathan Chan PART 2

🎙️ Tune in to learn how real-world validated tools can revolutionize psoriatic arthritis management, and the potential for enduring change within the dermatology community in PART 2.

🎧 🎉The discussion takes a significant turn as we delve into the complexities that emerge in treatment strategies, especially in the gap between patient referrals and confirmations of diagnosis. The challenge of masking symptoms and determining the right treatment pathway is examined, stressing the importance of understanding both skin and joint conditions in these patients.

🧵Join us for a dive with eminent psoriatic arthritis experts, Dr. Jan Dutz and Dr. Jonathan Chan. Their unique real-world model of care has caught the attention of our listeners, and in this episode, we finally unravel the inner workings of their combined dermatology and rheumatology clinic.

🫳After countless requests, we've garnered insights into how they run their clinic, how they manage their team, and if this model is sustainable? But that's not all.

🛎️Our dynamic derm-rheum tag team outline compare the practical utility of three different screening tools, in over 50 dermatologists' offices nationwide. Before participating in the project, some dermatologists expressed reservations regarding the perceived time-consuming nature of these tools, the potential for low yield in their population, and a general lack of habitual use or reminders.

• Is this model scalable? What potential barriers stand in its way?  
• And we delve into the intricacies of PSA screening tools – where's the optimal place for deployment? Where can they make the most impact?

🎙️🎙️Looking Forward: A critical question remains whether this change is short-term or will translate into long-term behavioral change?

Warm up those ear phones for PART 2! 

Exclusive to the Skin and Joints Podcast.

Episode supported by Novartis.

📻www.skinandjoints.ca

✉️[email protected]

🎧 🎉🎙️ Breaking Ground: A Co-Managed Approach to Psoriatic Arthritis - Real World Insights from Dr. Jan Dutz and Dr. Jonathan Chan PART 1

🎧 🎉We're excited to bring you a first-hand look at a unique model of care that's transforming the lives of psoriatic arthritis patients.

🧵Join us for a dive with eminent psoriatic arthritis experts, Dr. Jan Dutz and Dr. Jonathan Chan. Their unique real-world model of care has caught the attention of our listeners, and in this episode, we finally unravel the inner workings of their combined dermatology and rheumatology clinic.

🫳After countless requests, we've garnered insights into how they run their clinic, how they manage their team, and if this model is sustainable? But that's not all.

🛎️Be the first to hear the exclusive findings from a trailblazing real world study that the collaboration of over 50 dermatologists. The focus?  The real world use of PsA screening tools and the early detection of psoriatic arthritis that has the potential to revolutionize psoriatic arthritis detection in clinic.

🛎️This episode is an extension of our conversation with Dr. Dutz from last year, where he unveiled the concept of their model and discussed the validated tools used within their practice. Now, they've turned concept into reality, and we're here to unpack it all.

• Is this model scalable? What potential barriers stand in its way?  
• And we delve into the intricacies of PSA screening tools – where's the optimal place for deployment? Where can they make the most impact?

🎙️🎙️This episode is more than just a conversation - it's a paradigm shift in the treatment of psoriatic disease and psoriatic arthritis.  

🎙️🎙️Get ready for a world-exclusive reveal as we break the results of this ground-breaking real world study right here on our podcast for the first time.

Episode supported by Novartis.

📻www.skinandjoints.ca

✉️[email protected]

🔊🎧 BRACE YOUR EARS FOR #ROUND 2 🎧🔊

💡💼🌐 We're thrilled to announce the Skin and Joints Podcast back on the airwaves this week with dynamic #dermatology duo, Dr.Melinda Gooderham and Dr.Geeta Yadav for round 2! 🩺

🌊💡Join us as we sail the "#Psoriasis Sea" as we navigate what you need to know #roflumilast's long-term performance.

🎧Not only are we dropping anchor to delve into what you need to know about its #side effects, but we're also setting up the lighthouse to guide you through their manageability

🧑‍🦱🧭We've got the lifeboat you need: our experts will peel back the layers and offer insights into the #topical cream's effectiveness in #plaquePsO #skin #clearance and #itch #reduction. So, if you've been scratching your head 🧑‍🦱 over #psoriasis, it's time to stop!

𝙀𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣? 𝙊𝙧 𝙥𝙤𝙨𝙨𝙞𝙗𝙡𝙮 #𝙧𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙞𝙣 the way we treat #𝙋𝙨𝙤𝙧𝙞𝙖𝙨𝙞𝙨?

🧐🔬🦠 Dr.Geeta Yadav and Dr. Melinda Gooderham are 𝘀𝗼𝗼𝗻 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝘀𝗽𝗶𝗹𝗹 𝘁𝗵𝗲 𝗯𝗲𝗮𝗻𝘀  𝗼𝗻 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝘀𝗲𝗲 𝘁𝗵𝗶𝘀 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆'𝘀 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝗻 𝗺𝗮𝗸𝗶𝗻𝗴 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗳𝗼𝗿 𝗼𝘂𝗿 #𝗽𝗹𝗮𝗾𝘂𝗲𝗣𝘀𝗢 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀

⛵🧭Get ready to set sail with us. This is a conversation that's more than just skin-deep! 🗓️👂

#SkinAndJointsPodcast #Dermatology #Psoriasis #Roflumilast #Healthcare #StayTuned #Podcast #Medicine #SkinHealth #PSO #PDE4inhibitor #innovationmatters


Only on the Skin and Joints Podcast !

 

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

ABOUT Dr. Geeta Yadav, MSc, MD, FRCPC ( Dermatology)

Toronto, ON

Dr. Geeta Yadav is an expert in both medical and cosmetic dermatology and founder of FACET Dermatology in Toronto. . A second-generation Canadian, her interest in under-serviced communities and treating BIPOC patients was inspired by her childhood travels to India. She holds a master’s degree in International Health from Johns Hopkins and completed her dermatology training at the University of Toronto, where she still teaches today. Dr. Yadav is a fellow of the Royal College of Physicians and Surgeons, the American Academy of Dermatology, and the European Academy of Dermatology and Venereology. She has a special interest in skin of color and has been quoted in numerous main stream publications including the New York Times, Wall Street Journal, Allure, Vanity Fair and Cosmopolitan.

When she’s not working, she volunteers as an Alumni Governor at the University of Toronto. She also loves running, dancing, and spending time with her husband and three young children. 

▶️Episode supported by Arcutis.

📻www.skinandjoints.ca

✉️[email protected]

🎧 🎉TYK-TOK we’re ready to rock PART 2!

🎙️🎙️ The Skin and Joints Podcast Team continues the conversation with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.

 🛎️ Deucravacitinib is finally here! And we're going to be looking at fresh new data that could change your clinical practice.  We also break it down with our expert Faculty so you don't need to :) 

🧵Where do our experts see the overall place  deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world?

🧵How does it compare with other biologics and non-biologic treatments?

🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? 

Episode Learning Objectives

• Describe the overall place of deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world
• Examine the clinical efficacy associated with deucravacitinib and other select  biologic and nonbiologic treatments in patients with moderate to severe PsO
• Explore the correlations between responses on clinical and patient reported outcome (PRO) measures from  pooled data from POETYK PSO-1 and PSO-2 pivotal trials
• Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis  subgroup analyses pooled PSO-1 and PSO-2 data 

📻www.skinandjoints.ca

✉️[email protected]